

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Maureen S. Gibbons
Type or print name

Maureen S. Gibbons
Signature

January 6, 2005
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

PURANDARE ET AL.

APPLICATION NO: 10/761,990

FILED: JANUARY 21, 2004

FOR: METHODS FOR INHIBITING PROTEASOME

Mail Stop **Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3453


Maureen S. Gibbons
Maureen S. Gibbons
Attorney for Applicants
Reg. No. 44,121

Date: January 6, 2005

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOCKET NO.
LD0325 NP
APPLICATION NO.
10/761,990
APPLICANT
PURANDARE ET AL.
FILING DATE
JANUARY 21, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	5,861,380	1/19/99	Gyorkos et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AB	FR 2 758 329	7/17/98	France			<input type="checkbox"/>	<input type="checkbox"/>
	AC	WO 93/21213	10/28/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AD	WO 93/21214	10/28/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AE	WO 95/09634	4/13/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AF	WO 97/43310	11/20/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AG	WO 98/46630	10/22/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AH	WO 98/17679	4/30/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AI	WO 98/22496	5/28/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	WO 98/24806	6/11/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 99/07733	2/18/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 99/07734	2/18/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 01/07407	2/1/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AN	Ingallinella et al., "Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products", Biochemistry, Vol. 37, No. 25, pp. 8906-8914, 1998.
AO	Matteson et al., "Homologation of Boronic Esters to α -Chloro Boronic Esters", Organometallics, Vol. 2, pp. 1529-1535, 1983.
AP	Matteson et al., "Carbanions from α -Phenylthio Boronic Esters as Synthetic Intermediates", Vol. 1, pp. 280-288, 1982.
AQ	Steinkühler et al., "Product Inhibition of the Hepatitis C Virus NS3 Protease", Biochemistry, Vol. 37, No. 25, pp. 8899-8905, 1998.
AR	Llinas-Brunet et al., "Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease", Bioorganic & Medicinal Chemistry Letters, Vol. 8, pp. 1713-1718, May 29 1998.


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)


 ATTY. DOCKET NO.
 LD0325 NP
 APPLICATION NO.
 10/761,990
 APPLICANT
 PURANDARE ET AL.
 FILING DATE
 JANUARY 21, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AS	U.S. Patent Application No. 10/010,184 (BMS Docket No. PH7087A CIP)	Filed 12/6/01	Priestly et al.			
	AT						
	AU						
	AV						
	AW						
	AX						
	AY						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AZ	WO 02/48157	6/20/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BA	WO 01/39773	6/7/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BB	WO 01/07407	2/1/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BC						<input type="checkbox"/>	<input type="checkbox"/>
	BD						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BE	Steinkühler et al., "In Vitro Activity of Hepatitis C Virus Protease NS3 Purified from Recombinant Baculovirus-infected Sf9 Cells", The Journal of Biological Chemistry, Vol. 271, No. 11, pp. 6367-6373.
	BF	
	BG	
	BH	

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.